The case for Inovio
Like Intrexon, Inovio has seen its revenue grow tremendously. The biotech reported total revenue of $40.5 million in 2015, a year-over-year increase of almost 290%. Practically all of the revenue, though, stemmed from collaborative development agreements and grants rather than products on the market.
Inovio's Zika virus vaccine has received plenty of attention lately even though the vaccine is still in pre-clinical testing. The company's lead product is cervical dysplasia vaccine VGX-3100. Inovio plans to begin a phase 3 pivotal trial this year. Analysts think that VGX-3100 could hit peak annual sales of around $500 million if approved.
The biotech also claims multiple candidates in its pipeline, although they're all in early-stage development. INO-3112, a combination of VGX-3100 and a DNA-based immune activator, caught the attention of AstraZeneca's MedImmune division. MedImmune is collaborating with Inovio on a couple of phase 1 studies of INO-3112 focusing on cervical cancer and head and neck cancer.
Inovio's pipeline could provide some positive catalysts in 2016. The company expects to report interim data from a phase I study of INO-5150 in treating prostate cancer as well as interim data from a phase 1 study of INO-1400 in treating breast, lung, and pancreatic cancer later this year.
Losses continue to be the story for Inovio, but the situation is improving. It lost $29.2 million in 2015, but that was better than the $36.1 million loss from the prior year.
Analysts in general have a brighter outlook for Inovio than they do for Intrexon. That optimism likely comes largely from the prospects for VGX-3100 and Inovio's position as a leader in the race to develop a Zika virus vaccine.
Inovio's stock is up big year to date, while Intrexon's is down. Over 29% of Intrexon's float has been sold short compared to 16% for Inovio. Following the crowd isn't always the best strategy, but in this case, I agree with the apparent market consensus that Inovio is the better pick.
VGX-3100 is promising, as are several other candidates in Inovio's pipeline. The biotech appears to be in pretty good shape to fund operations long enough to wrap up the phase 3 study of its lead product. My hunch is that Inovio's stock could get more boosts from results to be announced later this year.
As mentioned at the beginning of this article, it's too early to know for sure which company will be the big winner in the fight against the Zika virus. However, if I had to place a bet right now, my money would be on Inovio.
Inovio, like Intrexon, isn't without its risks. VGX-3100 might run into problems in phase 3. Early-stage results for other vaccines might be disappointing. Issues could emerge with the Zika vaccine. All that being said, I still like Inovio's chances and think this could be a good pick for long-term investors
Please consider Partnering up, let.. this product grow as it should.At this rate I don't see much of a future w/constant r/s
Sentiment: Strong Buy
Quite a Circus here pat......seems they bring out the Lions when they start running out of steam and ideas.. Good luck to you..I hope and know you will be rewarded at the end of this adventure ,as all long will,
It will be sweet, and profitable.
Sentiment: Strong Buy
sell it or partner up.Dont loose all our money..what r you waiting for? you have a penny left..wouldn't be me..don't let a good product go away..
suks they do..
According to TipRanks who tracks the performance of analysts and other financial experts, the analyst consensus on Inovio Pharmaceuticals is Strong Buy and the average price target is $14.00, representing a %0.36 upside. The data is based on 3 analysts that rated Inovio Pharmaceuticals in the last 3 months.See the consensus rating of analysts covering the INO stock.
In taking a look at where the stock might be headed, analysts have a consensus price target of $18.6 on the shares. The most bullish brokerage firm has a $31 target, while the most bearish sees the stock headed towards $13. This is according to the 5 estimates taken into consideration by Zacks Research.
In terms of Buy/Sell recommendations, analysts have a consensus rating of 1. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 5 recommendations taking into account in order to arrive at this number. Of the 5, 5 have a Strong Buy rating and 0 are rating it a Buy.
Why don't you go after the "point of view",they wrote it .The date got by me and it was a typo.please unload your anger on someone who needs it.You should have focused on the point of view,not me. but its ok..have a nice day..
Go to the point of view article and read it.. or google "inovio pharmaceuticals june 16 2016 and read it.I will except apologies between 11am N 2PM TODAY..THANKS FOR THE GOOD FAITH..